2/14/2020 2:01:52 AM
AstraZeneca Q4 Reported EPS $0.24; Core EPS $0.89
1/27/2020 2:07:43 AM
AstraZeneca: Phase II DESTINY-Gastric01 Trial Of Enhertu Vs Chemotherapy Met Primary Endpoint
1/27/2020 2:05:54 AM
AstraZeneca Sells Inderal, Tenormin, Tenoretic, Zestril And Zestoretic To Atnahs
1/27/2020 2:04:33 AM
AstraZeneca: Brilinta Met Primary Endpoint In Phase III THALES Trial In Stroke
1/27/2020 1:17:00 AM
Allergan Enters Definitive Agreements To Divest Brazikumab And Zenpep
1/20/2020 2:05:46 AM
AstraZeneca: Lynparza Regulatory Submission Granted Priority Review In US
1/20/2020 2:04:39 AM
AstraZeneca: Imfinzi And Tremelimumab Granted Orphan Drug Designation In US
1/13/2020 2:05:56 AM
AstraZeneca Provides Update On Phase III STRENGTH Trial For Epanova In Mixed Dyslipidaemia
1/13/2020 2:05:21 AM
AstraZeneca Says SNDA For Lynparza In Combination With Bevacizumab Accepted And Granted Priority Review In The US
1/6/2020 2:09:23 AM
AstraZeneca: FDA Accept SNDA And Granted Priority Review For Farxiga
1/6/2020 2:08:22 AM
AstraZeneca Says Lokelma Approved In China For Adult Patients With Hyperkalaemia